Mechanism of statin-induced myopathy investigated using microarray technology

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 1, 2009, Pages 30-32

  Kohro, Takahide ^a   Yamazaki, Tsutomu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE; FLICE INHIBITORY PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RNA; SIMVASTATIN; UBIDECARENONE;

APOPTOSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA MICROARRAY; DRUG EFFICACY; EDITORIAL; HUMAN; INCIDENCE; LIVER DYSFUNCTION; MITOCHONDRIAL RESPIRATION; MUSCLE CELL; MYOPATHY; MYOTUBE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RHABDOMYOLYSIS; RNA EXTRACTION;

EID: 67549088680     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E812     Document Type: Editorial

References (27)

1. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361:1149-1158
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333:1301-1307
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344:1383-1389
4. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352:1425-1435
5. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002; 287:3215-3222
6. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol, 2006; 48:438-445
7. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368:1155-1163
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359:2195-2207
9. Black C, Jick H: Etiology and frequency of rhabdomyolysis. Pharmacotherapy, 2002; 22:1524-1526
10. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA, 2004; 292:2585-2590
11. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol, 2006; 97:52C-60C
12. Chang JT, Staffa JA, Parks M, Green L: Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf, 2004; 13:417-426
13. Mangravite LM, Krauss RM: Pharmacogenomics of statin response. Curr Opin Lipidol, 2007; 18:409-414
14. Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, Tsujita Y: Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl), 1993; 193:263-273
15. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ: Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during shortterm simvastatin treatment in humans. Clin Pharmacol Ther, 1995; 57:62-66
16. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ: The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol, 1996; 77:851-854
17. Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol, 2007; 99:1409-1412
18. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, Koizumi J: Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis, 2007; 195:e182-189
19. Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, Scott RS: Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol, 2007; 100:1400-1403
20. Flint OP, Masters BA, Gregg RE, Durham SK: Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol, 1997; 145:91-98
21. Baker SK: Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve, 2005; 31:572-580
22. Yu: An investigation of gene expression. Journal of Atherosclerosis and Thrombosis, 2008
23. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol, 2006; 291:C1208-1212
24. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet, 2000; 25:25-29
25. Dressman HK, Muramoto GG, Chao NJ, Meadows S, Marshall D, Ginsburg GS, Nevins JR, Chute JP: Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med, 2007; 4:e106
26. Ashley EA, Ferrara R, King JY, Vailaya A, Kuchinsky A, He X, Byers B, Gerckens U, Oblin S, Tsalenko A, Soito A, Spin JM, Tabibiazar R, Connolly AJ, Simpson JB, Grube E, Quertermous T: Network analysis of human in-stent restenosis. Circulation, 2006; 114:2644-2654
27. Rhee SY, Wood V, Dolinski K, Draghici S: Use and misuse of the gene ontology annotations. Nat Rev Genet, 2008; 9:509-515